Clinical efficacy of loperamide hydrochloride combined with Tongxiening Granules in treatment of patients with diarrhea-predominant irritable bowel syndrome
-
摘要:目的
观察盐酸洛哌丁胺联合痛泻宁颗粒对腹泻型肠易激综合征(IBS)的临床疗效。
方法收集60例腹泻型IBS患者的临床资料，按照治疗方案的不同将患者分为观察组(盐酸洛哌丁胺与痛泻宁颗粒联用)和对照组(盐酸洛哌丁胺单用)，每组30例。治疗4周后，评估并比较2组患者治疗前后腹痛评分、腹泻评分、症状总评分。
结果治疗前，2组患者腹痛评分、腹泻评分、症状总评分比较，差异无统计学意义(P>0.05); 对照组治疗后的腹痛评分、腹泻评分、症状总评分与治疗前比较，差异无统计学意义(P>0.05); 治疗后，观察组腹痛评分、腹泻评分、症状总评分均低于治疗前，且均低于对照组，差异有统计学意义(P < 0.05)。用药期间, 2组患者均未观察到明显不良反应。
结论盐酸洛哌丁胺与痛泻宁颗粒联用对腹泻型IBS患者疗效显著，且用药安全性良好。
Abstract:ObjectiveTo observe the clinical efficacy of loperamide hydrochloride combined with Tongxiening Granules in the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS).
MethodsClinical materials of 60 patients with diarrhea-predominant IBS were collected, and they were divided into observation group (treated with loperamide hydrochloride and Tongxiening Granules) and control group (treated with loperamide hydrochloride only) according to different therapeutic methods, with 30 cases in each group. After 4 weeks of treatment, the abdominal pain score, diarrhea score and total symptom score before and after treatment were evaluated and compared between two groups.
ResultsBefore treatment, there were no significant differences in the abdominal pain score, diarrhea score and total symptom score between the two groups (P>0.05); there were no significant differences in the abdominal pain score, diarrhea score and total symptom score before and after treatment in the control group (P>0.05); after treatment, the abdominal pain score, diarrhea score and total symptom score were significantly lower than those before treatment in the observation group, and these indexes in the observation were also significantly lower than those in the control group (P < 0.05). During the medication, no obvious adverse reactions were observed in both groups.
ConclusionLoperamide hydrochloride combined with Tongxiening Granules is effective in the treatment of patients with diarrhea-predominant IBS, and the safety of medication is good.
-
-
表 1 腹痛评分标准
腹痛程度 发作次数 持续时间 疼痛范围(部位) 评分 无腹痛 0次/周 0 d/周 0个 0分 轻度 1~2次/周 < 1 d/周 1个 1分 中度 3~4次/周 1~2 d/周 2~3个 2分 重度 ≥5次/周 ≥3 d/周 ≥3个 3分 
下载: 导出CSV
表 2 2组患者治疗前后腹痛评分、腹泻评分和症状总评分比较(x±s)
分 组别 时点 腹痛评分 腹泻评分 症状总评分 对照组(n=30) 治疗前 9.83±1.44 11.57±1.38 21.40±1.96 治疗后 9.03±1.71 10.70±1.29 19.73±2.18 观察组(n=30) 治疗前 9.47±1.91 10.97±1.22 20.43±2.30 治疗后 1.03±0.72*# 0.93±1.02*# 1.97±1.22*# 与治疗前比较, *P < 0.05; 与对照组比较, #P < 0.05。
下载: 导出CSV
-
[1] 王克俭, 杨勤. 疏肝和中汤治疗肝郁脾虚证腹泻型肠易激综合征的疗效观察[J]. 实用临床医药杂志, 2021, 25(23): 58-61, 68. doi: 10.7619/jcmp.20213488 [2] 中华中医药学会脾胃病分会, 温艳东, 李保双, 等. 消化系统常见病肠易激综合征中医诊疗指南(基层医生版)[J]. 中华中医药杂志, 2020, 35(7): 3518-3523. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202007066.htm [3] 张璐, 段丽萍, 刘懿萱, 等. 中国人群肠易激综合征患病率和相关危险因素的Meta分析[J]. 中华内科杂志, 2014, 53(12): 969-975. doi: 10.3760/cma.j.issn.0578-1426.2014.12.011 [4] 王喜红, 谢春娥, 薛晓轩, 等. 肠易激综合征的中西医治疗进展[J]. 西部中医药, 2020, 33(3): 156-159. https://www.cnki.com.cn/Article/CJFDTOTAL-GSZY202003044.htm [5] 李文平. 培菲康联合曲美布汀对腹泻型肠易激综合征的疗效[J]. 检验医学与临床, 2022, 19(19): 2683-2686. doi: 10.3969/j.issn.1672-9455.2022.19.024 [6] 刁俊杰. 肠易激综合征中医证治的现代文献系统评价研究[D]. 广州: 广州中医药大学, 2016. [7] 徐朝阳. 痛泻宁颗粒联合美沙拉嗪治疗腹泻型肠易激综合征临床研究[J]. 新中医, 2020, 52(19): 78-80. https://www.cnki.com.cn/Article/CJFDTOTAL-REND202019023.htm [8] 中华医学会消化病学分会胃肠功能性疾病协作组, 中华医学会消化病学分会胃肠动力学组. 2020年中国肠易激综合征专家共识意见[J]. 中华消化杂志, 2020, 40(12): 803-818. doi: 10.3760/cma.j.cn311367-20201116-00660 [9] 赵庆卫, 吕道仙. 痛泻宁颗粒联合金双歧治疗腹泻型肠易激综合征随机对照研究[J]. 中国医学创新, 2015, 12(26): 68-70, 71. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYCX201526023.htm [10] TANG X D, ZHANG S S, HOU X H, et al. Post-marketing re-evaluation of tongxiening granules in treatment of diarrhea-predominant irritable bowel syndrome: a multi-center, randomized, double-blind, double-dummy and positive control trial[J]. Chin J Integr Med, 2019, 25(12): 887-894.
[11] 黄文封, 黄适, 岳珍珍, 等. 安肠汤治疗腹泻型肠易激综合征(肝郁脾虚证)的理论探讨与临床应用[J]. 辽宁中医杂志, 2020, 47(1): 56-58. https://www.cnki.com.cn/Article/CJFDTOTAL-LNZY202001020.htm [12] 周启航. 灸脐联合七味白术散治疗脾虚湿盛型腹泻型肠易激综合征的临床观察[J]. 实用临床医药杂志, 2021, 25(5): 37-39. doi: 10.7619/jcmp.20200887 [13] 张莎. 中医药治疗腹泻型肠易激综合征的系统评价[D]. 西安: 中国人民解放军空军军医大学, 2017. [14] 苗艳芳, 王玉贤, 张声生. 痛泻要方对腹泻型肠易激综合征大鼠内脏敏感性及5-羟色胺、5-羟色胺转运体蛋白的影响[J]. 国际中医中药杂志, 2021, 43(12): 1209-1214. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZK202005033.htm [15] 陆敏, 杨友丽, 苏静, 等. 痛泻宁颗粒联合米曲菌胰酶片治疗腹泻型肠易激综合征效果研究[J]. 医药论坛杂志, 2021, 42(20): 29-31. https://www.cnki.com.cn/Article/CJFDTOTAL-HYYX202120007.htm [16] 储浩然, 黄学勇, 李学军, 等. 艾灸治疗腹泻型肠易激综合征临床研究[J]. 安徽中医学院学报, 2011, 30(6): 33-35. https://www.cnki.com.cn/Article/CJFDTOTAL-AHZY201106014.htm [17] 张玉山, 李宝辉, 左春芳, 等. 痛泻宁颗粒联合氟哌噻吨美利曲辛片治疗腹泻型肠易激综合征70例[J]. 实用医药杂志, 2019, 36(10): 902-904. https://www.cnki.com.cn/Article/CJFDTOTAL-QEYY201910013.htm [18] TAN Y Q, CHEN H W, LI J, et al. Efficacy, chemical constituents, and pharmacological actions of Radix paeoniae Rubra and Radix paeoniae alba[J]. Front Pharmacol, 2020, 11: 1054. http://www.socolar.com/Article/Index?aid=100083091891&jid=100000008597
[19] 孙玉霞, 梁波, 文黛薇, 等. 基于网络药理学探究痛泻要方治疗腹泻型肠易激综合征的作用机制[J]. 中国中医急症, 2020, 29(9): 1533-1537. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJZ202009008.htm
计量
- 文章访问数: 179
- HTML全文浏览量: 90
- PDF下载量: 20
苏公网安备 32100302010246号
